From 2025 Prix Galien (the "Nobel Prize of Medicine") Candidates to Clinical Breakthroughs: Academic Value and New Hope of Ovarian Cancer Therapeutic Drugs
ImageThe candidate list for the 2025 Prix Galien, hailed as the "Nobel Prize of Medicine," was recently announced, once again drawing attention to innovative achievements in the global biopharmaceutical field. In the field of cancer treatment, ovarian cancer has long been regarded as the "king of gynecological cancers" due to its high recurrence rate and mortality. However, recent breakthroughs in drug research targeting this disease have not only brought survival opportunities to patients but also promoted the practice and development of precision cancer treatment theory at the academic level, becoming an important microcosm of biopharmaceutical innovation.
Behind the Prix Galien: Defining Medical Breakthroughs by Scientific Value
Established by the Galien Foundation in the United States, the Prix Galien is the highest honor in the pharmaceutical and biomedical industry. Its selection criteria have always focused on "scientific innovation" and "health impact" rather than commercial data. The 2025 candidate list covers categories such as Best Biotechnology Product and Best Pharmaceutical Product, all requiring achievements approved by the U.S. FDA in the past 5 years with significant potential impact on human health. This selection logic exactly echoes the core of research in the field of ovarian cancer treatment—overcoming clinical challenges with rigorous scientific evidence.
The biggest challenge facing ovarian cancer patients is the dilemma of treatment after recurrence: the efficacy of traditional chemotherapy declines sharply after multiple recurrences, and the median survival time of patients is often less than 1 year. In recent years, the emergence of a number of innovative drugs has broken this deadlock through precise targeting mechanisms, and their research results have become the focus of the biopharmaceutical field for "addressing unmet medical needs."
From Laboratory to Clinic: The Academic Breakthrough Path of Ovarian Cancer Drugs
In the wave of innovation in ovarian cancer treatment, a number of drugs have verified their academic value through large-scale clinical research, providing a solid evidence-based medical basis for precision medicine.
Individualized Maintenance Therapy: The Key to Extending Progression-Free Survival
The application of PARP inhibitors is a landmark breakthrough in ovarian cancer treatment. The NORA study, led by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, first confirmed the efficacy of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer at the international level. The study adopted an "individualized starting dose" regimen, reducing the risk of disease progression or death by 68% in the total population and significantly prolonging the median progression-free survival. This achievement not only filled the gap in data on Chinese patients but also provided scientific reference for the safe medication of patients with different body weights and platelet counts through dose optimization exploration, and was included in international clinical practice guidelines.
The FZOCUS-1 study of fluzoparib, a domestic original PARP inhibitor, innovatively adopted a "three-arm design" to compare the efficacy differences between single-agent maintenance, combination with anti-angiogenic drugs, and placebo. The results showed that fluzoparib monotherapy can significantly improve the progression-free survival of advanced patients after first-line chemotherapy. Its unique molecular structure innovation enhances drug stability while ensuring activity, providing a "structure-efficacy" optimization model for the research and development of original drugs.
Breaking Through Drug Resistance Barriers: New Drugs Rewrite the Fate of Recurrent Patients
For patients with multiply resistant recurrent ovarian cancer, the emergence of Antibody-Drug Conjugates (ADCs) has shown the potential of "precision blasting." In the PICCOLO study announced at the European Society for Medical Oncology (ESMO) Congress, the ADC drug mirvetuximab soravtansine (Elahere) targeting FRα protein showed strong efficacy in platinum-sensitive, FRα-positive recurrent patients: over 85% of patients had tumor shrinkage, 51.9% achieved significant remission, and the median survival time reached 27.2 months, doubling that of traditional treatment. More notably, regardless of the patient's HRD gene status (reflecting the DNA repair ability of cancer cells), even in drug-resistant populations previously treated with PARP inhibitors and bevacizumab, the drug can still maintain stable efficacy, breaking through the "drug resistance bottleneck" of traditional treatment and providing new ideas for precise intervention across treatment lines.
Extension of Academic Value: From Treatment Innovation to Theoretical Deepening
The significance of these drug studies goes far beyond the improvement of clinical efficacy, but also promotes the development of cancer treatment theory at the academic level.
As the final result of the Prix Galien approaches, it is highly anticipated whether the innovative achievements of ovarian cancer therapeutic drugs can win this honor. However, regardless of the ownership of the award, these studies have proven with solid data that from theoretical breakthroughs in basic research, to the optimization and iteration of clinical regimens, and to the tangible improvement of patients' quality of life, the core of biopharmaceutical innovation has always been "overcoming diseases with scientific power." In the future, with the integration and transformation of more interdisciplinary technologies, ovarian cancer treatment may usher in a more precise and efficient new era.
Article Source: Comprehensive collation from the official Prix Galien website, WuXi AppTec, and Shengnuo Family.